Skip to main content

Advertisement

Table 1 Patient characteristics

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Variable Total % Mean/median Range
Age (years) 5.77/5.16 1.23–13.35
 < 10 211 87.6   
 ≥ 10 30 12.4   
WBC 76.5/17 0.4–880
 < 50 × 109 161 66.8   
 ≥ 50 × 109 80 33.2   
Gender
 Female 103 43.5   
 Male 134 56.5   
Down syndrome
 No 224 94.5   
 Yes 13 5.5   
NCI risk
 Standard 145 61.2   
 High 92 38.8   
Steroid pretreatment
 No 231 97.5   
 Yes 6 2.5   
Immunophenotype
 B-cell 196 82.7   
 T-cell 41 17.3   
CNS status
 CNS1 185 78.1   
 CNS2 26 11.0   
 CNS3 24 10.1   
 Missing 2 0.8   
Testes (male only)
 Not involved 131 97.8   
 Involved 3 2.2   
Cytogenetic group
 Normal 41 17.3   
 Hyperdiploidy 64 27.0   
 Double trisomy (+) 36a    
 Double trisomy (−) 28a    
 ETV6/RUNX1 23 9.7   
 iAMP(21) 5b    
 t(1;19) 6 2.5   
 MLLR 9 3.8   
 Other 81 34.2   
 Hypodiploidy (< 44) 0 0.0   
 Not available 9 3.8   
 Philadelphia 4 1.7   
  1. aHD double trisomy (+) and (−) were combined into a single hyperdiploidy (HD) group for analysis
  2. biAMP(21) was combined with “Others” group for analysis